For Antares Pharma Inc. [ATRS], Analyst sees a rise to $7. What next?

Related

Antares Pharma Inc. [NASDAQ: ATRS] slipped around 0.0 points on Friday, while shares priced at $5.57 at the close of the session, down 0.00%. The company report on April 13, 2022 that Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored

Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond.

Augments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing Potential .

Antares Pharma Inc. stock is now 56.02% up from its year-to-date (YTD) trading value. ATRS Stock saw the intraday high of $5.57 and lowest of $5.55 per share. The company’s 52-week high price is 5.59, which means current price is +79.10% above from all time high which was touched on 04/13/22.

Compared to the average trading volume of 3.54M shares, ATRS reached a trading volume of 13724079 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Antares Pharma Inc. [ATRS]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ATRS shares is $5.95 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ATRS stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Truist have made an estimate for Antares Pharma Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 16, 2021. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $5 to $3.50. The new note on the price target was released on October 23, 2017, representing the official price target for Antares Pharma Inc. stock. Previously, the target price had yet another raise to $5, while H.C. Wainwright analysts kept a Buy rating on ATRS stock.

The Average True Range (ATR) for Antares Pharma Inc. is set at 0.16, with the Price to Sales ratio for ATRS stock in the period of the last 12 months amounting to 5.14. The Price to Book ratio for the last quarter was 5.41, with the Price to Cash per share for the same quarter was set at 0.40. Price to Free Cash Flow for ATRS in the course of the last twelve months was 31.53 with Quick ratio for the last quarter at 2.80.

How has ATRS stock performed recently?

Antares Pharma Inc. [ATRS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.18. With this latest performance, ATRS shares gained by 39.25% in over the last four-week period, additionally plugging by 48.53% over the last 6 months – not to mention a rise of 40.66% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATRS stock in for the last two-week period is set at 80.34, with the RSI for the last a single of trading hit 83.31, and the three-weeks RSI is set at 77.64 for Antares Pharma Inc. [ATRS]. The present Moving Average for the last 50 days of trading for this stock 4.05, while it was recorded at 5.57 for the last single week of trading, and 3.78 for the last 200 days.

Antares Pharma Inc. [ATRS]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Antares Pharma Inc. [ATRS] shares currently have an operating margin of +14.86 and a Gross Margin at +62.32. Antares Pharma Inc.’s Net Margin is presently recorded at +25.16.

Return on Equity for this stock inclined to 31.40, with Return on Assets sitting at 19.70.

Antares Pharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.80 and a Current Ratio set at 3.00.

Insider trade positions for Antares Pharma Inc. [ATRS]

There are presently around $482 million, or 52.40% of ATRS stock, in the hands of institutional investors. The top three institutional holders of ATRS stocks are: BLACKROCK INC. with ownership of 12,023,196, which is approximately 1.244% of the company’s market cap and around 2.40% of the total institutional ownership; RUBRIC CAPITAL MANAGEMENT LP, holding 10,800,000 shares of the stock with an approximate value of $60.16 million in ATRS stocks shares; and VANGUARD GROUP INC, currently with $47.06 million in ATRS stock with ownership of nearly -1.855% of the company’s market capitalization.

Positions in Antares Pharma Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 80 institutional holders increased their position in Antares Pharma Inc. [NASDAQ:ATRS] by around 11,132,189 shares. Additionally, 73 investors decreased positions by around 7,227,409 shares, while 38 investors held positions by with 68,093,147 shares. The mentioned changes placed institutional holdings at 86,452,745 shares, according to the latest SEC report filing. ATRS stock had 18 new institutional investments in for a total of 1,469,556 shares, while 22 institutional investors sold positions of 2,142,204 shares during the same period.